Safety and efficacy of the anti-PDL1 antibody atezolizumab versus chemotherapy were assessed in the phase III trial IMvigor211 in 931 patients with metastatic urothelial carcinoma who had progressed after platinum-based chemotherapy. In patients with PDL1 expression on ≥5% of tumour-infiltrating immune cells, overall survival did not differ between treatment arms (stratified HR 0.87, 95% CI 0.63–1.21), precluding further formal analysis. In the intention-to-treat population, grade 3–4 treatment-related adverse events were lower in the atezolizumab arm (20%) than in the chemotherapy arm (43%). Exploratory analysis of this population showed durable responses to atezolizumab.
References
Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)33297-X (2017)
Rights and permissions
About this article
Cite this article
Thoma, C. IMvigor211 trial outcomes reported. Nat Rev Urol 15, 137 (2018). https://doi.org/10.1038/nrurol.2017.225
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.225